Linked Life Data

15160944

Source:http://linkedlifedata.com/resource/pubmed/id/15160944

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-5-26
pubmed:abstractText
Alemtuzumab, the monoclonal anti-CD52 antibody, has clinical activity in B-cell and T-cell malignancies at the dose of 30 mg three times weekly for 9-12 weeks. This standard regimen induced responses usually shorter than 6 months. To prolong time to progression, we initialized a phase II study with an identical initial scheme until partial response, followed by a maintenance therapy lasting at least 4 months. Eleven heavily pretreated patients (8 with B-chronic lymhocytic leukemia (B-CLL) and 3 with small lymphoctyic lymphoma (SLL)) have been treated with this maintenance regimen (MR patients) and were retrospectively compared to 5 patients (3 B-CLL and 2 SLL) treated with the standard regimen (SR patients). Patients characteristics before treatment were identical in both groups. Objective response was reached by 9 (82%) MR patients and 3 (60%) SR patients (p NS). After the treatment, 8 (73%) MR patients and all SR patients progressed with a median time at 12.2 months and 3 months respectively. Survival time from alemtuzumab was significatively different (P < 0.005). None of the patients died in the MR group with a median follow-up at 16 months. In the SR group, the median survival from alemtuzumab was 5.9 months. We did not observe any differences in terms of hematological toxicites and infections between the two groups. In conclusion, maintenance alemtuzumab therapy seems to increase the time to progression and the survival, without adding hematological toxicities and infectious complications. More patients are needed to confirm this observation.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1042-8194
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
711-4
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:15160944-Aged, pubmed-meshheading:15160944-Aged, 80 and over, pubmed-meshheading:15160944-Antibodies, Monoclonal, pubmed-meshheading:15160944-Antibodies, Monoclonal, Humanized, pubmed-meshheading:15160944-Antibodies, Neoplasm, pubmed-meshheading:15160944-Disease-Free Survival, pubmed-meshheading:15160944-Drug Administration Schedule, pubmed-meshheading:15160944-Female, pubmed-meshheading:15160944-Hematologic Diseases, pubmed-meshheading:15160944-Humans, pubmed-meshheading:15160944-Leukemia, Lymphocytic, Chronic, B-Cell, pubmed-meshheading:15160944-Male, pubmed-meshheading:15160944-Middle Aged, pubmed-meshheading:15160944-Opportunistic Infections, pubmed-meshheading:15160944-Remission Induction, pubmed-meshheading:15160944-Salvage Therapy, pubmed-meshheading:15160944-Survival Analysis
pubmed:year
2004
pubmed:articleTitle
Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
pubmed:affiliation
Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69495 Pierre-Benite, France. catherine.thieblemont@chu-lyon.fr
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Clinical Trial, Phase II